InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Veradermics, Inc

MANE Clue Score23
United States Fiscal year ends December CIK 0001827635
$130.90 +3.37% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $130.90 +118.24% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 4 Feb 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−26.8Net income−26.5EPS, diluted−37.05Fiscal year 2025Operating income−72.3Net income−70.0EPS, diluted−111.91
FY2024FY2025
Operating income −26.8 −72.3
Net income −26.5 −70.0
Growth
EPS, diluted −37.05 −111.91
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−23.7Capital expenditure0.0Free cash flow−23.7Fiscal year 2025Operating cash flow−71.6Capital expenditure−0.0Free cash flow−71.6
FY2024FY2025
Operating cash flow −23.7 −71.6
Capital expenditure 0.0 −0.0
Free cash flow −23.7 −71.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash53.1Shareholders’ equity−48.5Fiscal year 2025Cash21.8Shareholders’ equity−121.0
FY2024FY2025
Cash 53.1 21.8
Shareholders’ equity −48.5 −121.0

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−23.7 −71.6
Growth
Investment
0.0 −0.0
calc −23.7 −71.6
Growth
calc −32.14 −96.14
0.0 −118.9
Financing
60.5 159.1

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.